T. Rowe Price Associates’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16M | Sell |
735,698
-241,925
| -25% | -$5.25M | ﹤0.01% | 1005 |
|
|
2025
Q1 | $23.7M | Sell |
977,623
-237,815
| -20% | -$5.77M | ﹤0.01% | 914 |
|
|
2024
Q4 | $25.4M | Sell |
1,215,438
-18,945
| -2% | -$395K | ﹤0.01% | 932 |
|
|
2024
Q3 | $24.5M | Buy |
1,234,383
+1,531
| +0.1% | +$30.4K | ﹤0.01% | 952 |
|
|
2024
Q2 | $19.1M | Buy |
1,232,852
+13,434
| +1% | +$208K | ﹤0.01% | 972 |
|
|
2024
Q1 | $19.4M | Buy |
1,219,418
+22,860
| +2% | +$364K | ﹤0.01% | 982 |
|
|
2023
Q4 | $20.1M | Buy |
1,196,558
+18,390
| +2% | +$309K | ﹤0.01% | 955 |
|
|
2023
Q3 | $13.8M | Buy |
1,178,168
+76,778
| +7% | +$898K | ﹤0.01% | 1004 |
|
|
2023
Q2 | $14.8M | Buy |
1,101,390
+71,711
| +7% | +$964K | ﹤0.01% | 1008 |
|
|
2023
Q1 | $17.1M | Buy |
1,029,679
+78,905
| +8% | +$1.31M | ﹤0.01% | 956 |
|
|
2022
Q4 | $17.7M | Buy |
950,774
+935,316
| +6,051% | +$17.4M | ﹤0.01% | 942 |
|
|
2022
Q3 | $199K | Buy |
+15,458
| New | +$199K | ﹤0.01% | 2543 |
|